NextCell Pharma AB (“NextCell”) announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11.
NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient’s last visit is scheduled for the end of June/July 2020. Thereafter, data will be analyzed and results are expected to be presented in September.
NextCell is now preparing for the next step in the clinical trial program. In case of positive data from the phase II part, an application for a pivotal phase III study will be submitted.
In December 2019, NextCell presented positive efficacy data from the phase I part of the study. Although designed solely for safety analysis, a dose-dependent effect of treatment could be shown.
Stockholm Corporate Finance, in collaboration with Financial Hearings, arranges the Capital Market Day for the twelfth year in a row and offers investors, analysts and the media to meet companies in Life Science and Health Care. The seminar will take place at Berns in Stockholm 11-12 March and NextCell’s presentation will be held on 11 March at 11.15 AM.
The presentation can be followed via a webcast, see link below:
https://financialhearings.com/event/12253
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.se
